FDA approval timeline June 2023 : Phase 2 results in the New England Journal of Medicine 17.5% weight loss at 24 weeks December 2025 : TRIUMPH-4 results 28.7% weight loss March 2026 : TRANSCEND-T2D-1 results glycemic control + weight loss May 2026 : TRIUMPH-1 results up to 28.3% / 70 lbs over 80 weeks Late 2026 (est.) : Remaining TRIUMPH trials complete
NA-931s GIP receptor agonism is intended to boost the insulinotropic effect (helping to buffer blood sugar when glucagon is also stimulated) and potentially contribute to metabolic improvements in adipose tissue
Habib HA, Sanchiz J, Janiak C: [Cu 2 ( 5 -btb) (-OH) (-H 2 O)]: a two-dimensional coordination polymer built from ferromagnetically coupled Cu2 units (btb = benzene-1, 2, 3-tricarboxylate)
The 2004 study documented reduced loss of righting reflex, the rodent equivalent of losing consciousness from alcohol
According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]